JENNIFER MIRON: Open Payments
NPI 1336486752 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,257 in 90 payments from 16 companies in 2025. Trend: 2023 $1,780 · 2024 $1,917 · 2025 $2,257
Food & beverage: $2,173Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $843 |
| Ardelyx, Inc. | 12 | $307 |
| Janssen Biotech, Inc. | 11 | $306 |
| Regeneron Healthcare Solutions, Inc. | 5 | $146 |
| Aimmune Therapeutics, Inc. | 5 | $118 |
| Madrigal Pharmaceuticals | 3 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $94 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $72 |
| EVOKE PHARMA, INC. | 3 | $51 |
| Phathom Pharmaceuticals, Inc. | 2 | $43 |
Products named: RINVOQ, IBSRELA, TREMFYA, SKYRIZI, DUPIXENT, CREON, REZDIFFRA, ZENPEP.
Industry payments across TX — which companies pay providers there.
